Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(19):1545; doi:10.1093/jnci/92.19.1545
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 19, 1545, October 4, 2000
© 2000 Oxford University Press

IN THIS ISSUE

Geldanamycin/MAb Conjugate and HER2 Overexpression

Breast carcinomas that overexpress HER2, a membrane receptor with tyrosine kinase activity, are associated with poor prognosis. Inhibition of HER2 activity with anti-HER2 antibodies can reduce growth of tumors overexpressing HER2; however, the objective response rate is low. The antibiotic geldanamycin can also reduce HER2 activity, but it is highly toxic in vivo. To enhance the inhibitory activity of the antibody and to decrease the toxicity of free geldanamycin, Mandler et al. (p. 1573) coupled an anti-HER2 monoclonal antibody (MAb), e21, to geldanamycin to form an immunoconjugate. . . . [Full Text of this Article]

Health Outcomes After Prostate Cancer Treatment

Precursors of Gastric Cancer

Insulin-Related Proteins and Risk of Colorectal Cancer

Selecting Regimens for Phase III Trials for SCLC


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?